Here, we aimed to study whether the chronic administration of PPARγ agonist pioglitazone could influence renal EGR-1, STAT3 and AP-1 expression, and ameliorate renal fibrosis in TGF-β1 overexpressing mice. Here, FOS is linked to renal fibrosis.